Passage Bio, Inc. (PASG) Misses Q3 EPS by 8c

Passage Bio, Inc. (NASDAQ: PASG) reported Q3 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Passage Bio, Inc. (PASG) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• H.C. Wainwright Reiterates Buy Rating on Elicio Therapeutics (ELTX)
• Galmed completes Colospan acquisition under restructured terms